What is the efficacy and safety profile for the pediatric patient?
Cathflo’s efficacy and safety profile in pediatric patients in the Cathflo Pediatric Study (CAPS) demonstrated an 83% cumulative efficacy after up to 2 doses using a 2-hour dwell. Rates of adverse events were similar in pediatric and adult patients. Cathflo was studied in patients between 2 weeks and 17 years of age.1 *Study design: CAPS, a prospective, multicenter, open-label, single-arm study where two maximum does of 2 mg of alteplase was performed in patients between the age of 2 weeks and 17 with occluded catheters (N=310).
